- Home
- NMRA vs VNDA Comparison
NMRA vs VNDA Comparison
Compare NMRA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- VNDA
- Stock Information
- Founded
- NMRA 2019
- VNDA 2002
- Country
- NMRA United States
- VNDA United States
- Employees
- NMRA N/A
- VNDA N/A
- Industry
- NMRA
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- VNDA Health Care
- Exchange
- NMRA Nasdaq
- VNDA Nasdaq
- Market Cap
- NMRA 121.0M
- VNDA 261.7M
- IPO Year
- NMRA 2023
- VNDA 2006
- Fundamental
- Price
- NMRA $1.03
- VNDA $4.91
- Analyst Decision
- NMRA Buy
- VNDA Strong Buy
- Analyst Count
- NMRA 8
- VNDA 3
- Target Price
- NMRA $9.29
- VNDA $15.33
- AVG Volume (30 Days)
- NMRA 1.4M
- VNDA 388.0K
- Earning Date
- NMRA 08-05-2025
- VNDA 07-30-2025
- Dividend Yield
- NMRA N/A
- VNDA N/A
- EPS Growth
- NMRA N/A
- VNDA N/A
- EPS
- NMRA N/A
- VNDA N/A
- Revenue
- NMRA N/A
- VNDA $201,351,000.00
- Revenue This Year
- NMRA N/A
- VNDA $16.86
- Revenue Next Year
- NMRA N/A
- VNDA $39.78
- P/E Ratio
- NMRA N/A
- VNDA N/A
- Revenue Growth
- NMRA N/A
- VNDA 13.37
- 52 Week Low
- NMRA $0.61
- VNDA $3.81
- 52 Week High
- NMRA $17.19
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- NMRA 67.61
- VNDA 62.83
- Support Level
- NMRA $0.72
- VNDA $4.85
- Resistance Level
- NMRA $0.85
- VNDA $5.07
- Average True Range (ATR)
- NMRA 0.08
- VNDA 0.16
- MACD
- NMRA 0.02
- VNDA 0.02
- Stochastic Oscillator
- NMRA 100.00
- VNDA 76.81
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.